North Star Investment Management’s Moleculin Biotech MBRX Stock Holding History

North Star Investment Management’s Portfolio MBRX Stock Details MBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-1	Closed	-$9	–	1598
2025 Q3	$9	Hold	1	–	–	﹤0.01%	1317
2025 Q2	$5	Hold	1	–	–	﹤0.01%	1212
2025 Q1	$17	Hold	1	–	–	﹤0.01%	1194
2024 Q4	$29	Hold	1	–	–	﹤0.01%	1211
2024 Q3	$48	Hold	1	–	–	﹤0.01%	1174
2024 Q2	$60	Hold	1	–	–	﹤0.01%	1150
2024 Q1	$95	Hold	1	–	–	﹤0.01%	1219
2023 Q4	$215	Hold	1	–	–	﹤0.01%	1158
2023 Q3	$107	Hold	1	–	–	﹤0.01%	1254
2023 Q2	$145	Hold	1	–	–	﹤0.01%	1264
2023 Q1	$240	Hold	1	–	–	﹤0.01%	1267
2022 Q4	$265	Hold	1	–	–	﹤0.01%	1270
2022 Q3	$0	Hold	1	–	–	﹤0.01%	1160
2022 Q2	$0	Hold	1	–	–	﹤0.01%	1162
2022 Q1	$0	Hold	1	–	–	﹤0.01%	1184
2021 Q4	$0	Hold	1	–	–	﹤0.01%	1202
2021 Q3	$1K	Hold	1	–	–	﹤0.01%	1082
2021 Q2	$1K	Hold	1	–	–	﹤0.01%	1058
2021 Q1	$1K	Buy	+1	New	+$1.83K	﹤0.01%	1021

Other funds holding MBRX

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

EFG International Zurich $4.67B AUM

PWPS

Pinnacle Wealth Planning Services Mansfield, Ohio $968M AUM 19.1% 1-Year Est. Return

Rockefeller Capital Management New York $56.4B AUM 24.96% 1-Year Est. Return

North Star Investment Management's MBRX Position: Q4 2025 in Review

North Star Investment Management sold out of Moleculin Biotech (MBRX) in Q4 2025, closing a stake of 1 share — an estimated $9 sold.

North Star Investment Management first reported a position in MBRX in Q1 2021 and held it in 19 quarters. The position peaked at $1K in Q3 2021. 17 funds tracked by Wall St. Rank hold MBRX as of Q4 2025.

North Star Investment Management reported no remaining Moleculin Biotech position as of Q4 2025 after selling out during the quarter.
North Star Investment Management sold 1 Moleculin Biotech share in Q4 2025, an estimated $9.
North Star Investment Management first reported a position in Moleculin Biotech in Q1 2021 and held it in 19 quarters.
North Star Investment Management's Moleculin Biotech position peaked at $1K in Q3 2021.
17 funds tracked by Wall St. Rank held Moleculin Biotech as of Q4 2025.

Based on North Star Investment Management's 13F filing for Q4 2025, filed 30 Jan 2026.